ISIN | LU1280185064 |
---|---|
Valor Number | 29323856 |
Bloomberg Global ID | |
Fund Name | MFS Meridian Funds - Global Equity Income Fund A1 Acc |
Fund Provider |
MFS International Limited
London, United Kingdom Phone: +44 20 7429 7200 |
Fund Provider | MFS International Limited |
Representative in Switzerland |
Reyl & Cie S.A. Genève Phone: +41 22 816 80 00 |
Distributor(s) |
Carnegie Fund Services S.A. Genève 11 Phone: +41 22 705 11 77 |
Asset Class | Equities |
EFC Category | |
Distribution Policy | Accumulation |
Home Country | Luxembourg |
Issuing Condition | Combination of issuing commission charged by the fund management company and transaction fee charged by the fund |
Redemption Condition | Combination of redemption commission charged by the fund management company and transaction fee charged by the fund |
Investment Strategy *** | The Fund’s investment objective is to seek total return through a combination of current income and capital appreciation, measured in US dollars. The Fund invests primarily (at least 70%) in equity securities of companies located in developed and emerging market countries. The Fund normally primarily invests in income-producing equity securities. The Fund invests the majority of its assets in dividend-paying common stocks, but may invest in other types of income producing securities, including convertible securities, preferred stocks and equity interests in closed-ended real estate investment trusts (REITs) or equity securities of companies principally engaged in the real estate industry. The Fund may also invest in non-income-producing equity securities. |
Peculiarities |
Current Price * | 17.65 USD | 09.04.2025 |
---|---|---|
Previous Price * | 16.85 USD | 08.04.2025 |
52 Week High * | 19.49 USD | 27.09.2024 |
52 Week Low * | 16.85 USD | 08.04.2025 |
NAV * | 17.65 USD | 09.04.2025 |
Issue Price * | ||
Redemption Price * | ||
Closing Price * | ||
Indicative Minimum Price | ||
Fund Assets *** | 10,793,947 | |
Unit/Share Assets *** | 1,219,904 | |
Trading Information SIX |
YTD Performance | -2.59% |
31.12.2024 - 09.04.2025
31.12.2024 09.04.2025 |
---|---|---|
YTD Performance (in CHF) | -9.10% |
31.12.2024 - 09.04.2025
31.12.2024 09.04.2025 |
1 month | -7.35% |
10.03.2025 - 09.04.2025
10.03.2025 09.04.2025 |
3 months | -0.73% |
10.01.2025 - 09.04.2025
10.01.2025 09.04.2025 |
6 months | -8.55% |
09.10.2024 - 09.04.2025
09.10.2024 09.04.2025 |
1 year | -2.43% |
09.04.2024 - 09.04.2025
09.04.2024 09.04.2025 |
2 years | +8.62% |
11.04.2023 - 09.04.2025
11.04.2023 09.04.2025 |
3 years | +8.08% |
11.04.2022 - 09.04.2025
11.04.2022 09.04.2025 |
5 years | +61.19% |
09.04.2020 - 09.04.2025
09.04.2020 09.04.2025 |
Equity Participation Rate in % | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Share of Total Fund Assets in % | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Real Estate Rate in % | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
ADDI | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
ADDI Date |
AbbVie Inc | 3.39% | |
---|---|---|
Roche Holding AG | 3.15% | |
Kimberly-Clark Corp | 3.02% | |
Colgate-Palmolive Co | 2.93% | |
KDDI Corp | 2.85% | |
General Mills Inc | 2.66% | |
DBS Group Holdings Ltd | 2.43% | |
Manulife Financial Corp | 2.38% | |
Tesco PLC | 2.19% | |
Northern Trust Corp | 2.13% | |
Last data update | 28.02.2025 |
TER *** | 0.25% |
---|---|
TER date *** | 31.07.2024 |
Performance Fee *** | |
PTR | |
Max. Management Fee *** | 0.70% |
Ongoing Charges *** | 1.70% |
SRRI ***
|
|
SRRI date *** | 31.03.2025 |